Preferred Label : Anti-SIRPa Monoclonal Antibody DS-1103;
NCIt synonyms : Anti-SIRPalpha Monoclonal Antibody DS-1103;
NCIt definition : An immunoglobulin G4 (IgG4) monoclonal antibody targeting human signal-regulatory
protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing
and antineoplastic activities. Upon administration, anti-SIRPa monoclonal antibody
DS-1103 targets and binds to SIRPa, a cell surface protein expressed on macrophages,
thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47)
expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates
the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling
mediated by the binding of calreticulin (CRT), which is specifically expressed on
the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein
(LRP), expressed on macrophages, and results in macrophage activation and the specific
phagocytosis of tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor
type substrate 1, mediates negative regulation of phagocytosis, mast cell activation
and dendritic cell activation. CD47, also called integrin-associated protein (IAP),
is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem
cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression
of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation
and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.;
Molecule name : DS-1103a; DS 1103a; DS 1103; DS-1103;
NCI Metathesaurus CUI : CL1907454;
Origin ID : C200452;
UMLS CUI : C5854532;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
